Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trabedersen - Autotelic/Oncotelic

Drug Profile

Trabedersen - Autotelic/Oncotelic

Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisense

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antisense Pharma
  • Developer Autotelic; Oncotelic
  • Class Antineoplastics; Oligodeoxyribonucleotides; Thionucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II/III Malignant melanoma; Pancreatic cancer
  • Preclinical Ovarian cancer
  • No development reported Colorectal cancer
  • Discontinued Anaplastic astrocytoma

Most Recent Events

  • 23 Sep 2019 The US FDA grants Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma
  • 09 Sep 2019 Mateon Therapeutics plans a expanded access program for Pancreatic cancer
  • 25 Apr 2019 Oncotelic has been acquired by Mateon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top